Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
Dermata Therapeutics (NASDAQ:DRMA) announced the acceptance of its patent application by the Australian Patent Office for its Spongilla technology combination to treat acne. The patent, which follows a similar U.S. patent issuance, will automatically be granted in mid-January 2026 unless opposed.
The company plans to launch a once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit incorporating its Spongilla technology by mid-2026. This innovative treatment targets underlying acne mechanisms with enhanced precision, potentially offering improved outcomes and reduced side effects. The Australian market represents a significant opportunity with over 3.3 million people diagnosed with acne.
Dermata Therapeutics (NASDAQ:DRMA) ha annunciato l'accettazione da parte dell'Ufficio Australiano dei Brevetti della domanda di brevetto per la sua tecnologia Spongilla, una combinazione destinata al trattamento dell'acne. Il brevetto, che segue un'autorizzazione per un brevetto analogo negli Stati Uniti, verrà automaticamente concesso a metà gennaio 2026 salvo opposizioni.
L'azienda prevede di lanciare entro la metà del 2026 un kit anti-acne da banco (OTC) da utilizzare una volta a settimana, che integra la tecnologia Spongilla. Questo trattamento innovativo mira ai meccanismi di base dell'acne con una precisione maggiore, offrendo potenzialmente risultati migliori e meno effetti collaterali. Il mercato australiano rappresenta una notevole opportunità, con oltre 3,3 milioni di persone diagnosticate con acne.
Dermata Therapeutics (NASDAQ:DRMA) anunció la aceptación de su solicitud de patente por parte de la Oficina de Patentes de Australia para su tecnología Spongilla, una combinación destinada a tratar el acné. La patente, que sigue a una concesión de patente similar en Estados Unidos, se concederá automáticamente a mediados de enero de 2026 a menos que exista oposición.
La empresa planea lanzar a mediados de 2026 un kit de tratamiento para el acné de venta libre (OTC) de uso semanal que incorpore la tecnología Spongilla. Este tratamiento innovador aborda los mecanismos subyacentes del acné con mayor precisión, potencialmente con mejores resultados y menos efectos secundarios. El mercado australiano representa una oportunidad significativa, con más de 3,3 millones de personas diagnosticadas con acné.
Dermata Therapeutics (NASDAQ:DRMA)는 여드름 치료를 위한 Spongilla 기술 조합에 대한 특허 출원이 호주 특허청의 승인을 받았다고 발표했다. 미국에서 유사 특허가 이미 발급된 것을 따라 자동으로 2026년 1월 중순에 부여될 예정이며, 반대가 없으면 그러하다.
회사는 2026년 중반까지 Spongilla 기술을 도입한 주 1회 OTC(처방전 없이 구입 가능한) 여드름 치료 키트를 출시할 계획이다. 이 혁신적 치료법은 여드름의 기저 메커니즘을 더 높은 정밀도로 겨냥해 더 나은 결과와 부작용 감소를 제공할 가능성이 있다. 호주 시장은 여드름으로 진단받은 인구가 330만 명이 넘는 등 상당한 기회를 나타낸다.
Dermata Therapeutics (NASDAQ:DRMA) a annoncé l'acceptation de sa demande de brevet par l'Office australienne des brevets pour sa technologie Spongilla, une combinaison destinée au traitement de l'acné. Le brevet, qui fait suite à une délivrance de brevet similaire aux États‑Unis, sera automatiquement accordé à la mi-janvier 2026 sauf opposition.
L'entreprise prévoit de lancer d'ici la mi-2026 un kit anti-acné en vente libre (OTC) à usage une fois par semaine, intégrant la technologie Spongilla. Ce traitement innovant cible les mécanismes sous-jacents de l'acné avec une précision accrue, pouvant offrir de meilleurs résultats et moins d'effets secondaires. Le marché australien représente une opportunité importante, avec plus de 3,3 millions de personnes diagnostiquées d'acné.
Dermata Therapeutics (NASDAQ:DRMA) gab die Annahme ihres Patentantrags durch das australische Patentamt für die Spongilla-Technologie-Kombination zur Behandlung von Akne bekannt. Das Patent folgt auf eine ähnliche US-Patenterteilung und wird automatisch Mitte Januar 2026 erteilt, sofern kein Widerspruch erhoben wird.
Das Unternehmen plant die Einführung eines wöchentlichen OTC-Akne-Kits, das die Spongilla-Technologie integriert, bis Mitte 2026. Diese innovative Behandlung zielt mit erhöhter Präzision auf die zugrunde liegenden Mechanismen von Akne ab und könnte zu besseren Ergebnissen und weniger Nebenwirkungen führen. Der australische Markt bietet eine bedeutende Chance, da dort über 3,3 Millionen Menschen mit Akne diagnostiziert sind.
أعلنت Dermata Therapeutics (المدرجة في ناسداك: DRMA) قبول مكتب براءات الاختراع الأسترالي لطلبها الخاص بتقنية Spongilla المركبة لعلاج حب الشباب. يَأتي البراءة بعد إصدار مشابه في الولايات المتحدة، وسيُمنَح تلقائياً في منتصف يناير 2026 ما لم يعترض أحد.
تخطط الشركة لإطلاق مجموعة علاج لحب الشباب من النوع OTC تُباع بدون وصفة وتُستخدم مرة واحدة أسبوعياً، مع دمج تقنية Spongilla، بحلول منتصف 2026. يستهدف هذا العلاج المبتكر آليات حب الشباب الأساسية بدقة أعلى، مما قد يوفر نتائج أفضل وتقلل من الآثار الجانبية. يمثل السوق الأسترالي فرصة كبيرة مع أكثر من 3.3 مليون شخص تم تشخيصهم بحب الشباب.
Dermata Therapeutics（NASDAQ:DRMA）宣布澳大利亚专利局已接受其用于治疗痤疮的 Spongilla 技术组合的专利申请。该专利紧随美国类似专利的授予，将在2026 年 1 月中旬自动获得批准，除非有异议。
公司计划在 2026 年中旬之前推出一款每周使用一次的非处方 OTC 痤疮治疗套件，融入 Spongilla 技术。这一创新治疗通过更高精度针对痤疮的基本机制，可能带来更好的效果并减少副作用。澳大利亚市场具有重要潜力，诊断为痤疮的人数超过 330 万人。
- Patent application acceptance strengthens global intellectual property portfolio
- Large market opportunity with 3.3 million acne patients in Australia
- Planned launch of innovative once-weekly OTC treatment by mid-2026
- Additional patent applications pending in other jurisdictions
- Patent could face opposition within three months of acceptance publication
- Product launch not expected until mid-2026
Insights
Australian patent acceptance strengthens Dermata's IP portfolio for its novel Spongilla-based acne treatment ahead of planned 2026 OTC product launch.
The Australian Patent Office's acceptance of Dermata's application covering its Spongilla technology combination for acne treatment represents a significant expansion of the company's intellectual property protection beyond its existing U.S. patent. This development is strategically timed as Dermata pivots toward over-the-counter pharmaceutical products.
The accepted patent application, titled "Compositions and methods for the treatment of skin conditions" (Australian Patent Application No. 2019419387), will automatically issue in mid-January 2026 absent third-party opposition. This timeline aligns favorably with Dermata's stated product launch timeline of mid-2026 for its once-weekly OTC acne treatment kit.
Australia represents a meaningful market opportunity with over 3.3 million people diagnosed with acne. The patent acceptance strengthens Dermata's commercial potential in this region by providing market exclusivity for its technology. Additionally, the company has indicated that patent applications are pending in other jurisdictions, suggesting a comprehensive global IP strategy.
The company's approach focuses on targeting underlying acne mechanisms rather than symptoms alone, potentially offering improved efficacy with fewer side effects compared to traditional treatments. The once-weekly application schedule could provide a competitive advantage in the crowded acne treatment market by addressing patient compliance issues common with daily regimens.
While the Australian patent acceptance is promising, investors should note that commercial success depends on multiple factors including final product formulation, pricing strategy, marketing effectiveness, and competitive landscape when the product eventually launches in mid-2026.
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -
- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit, incorporating its Spongilla technology, in the middle of 2026 -
- Over 3.3 million people are diagnosed with acne in Australia -
SAN DIEGO, CA, AL / ACCESS Newswire / October 2, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has accepted Dermata's patent application for its Spongilla technology combination as a method for treating acne. The accepted patent application, entitled "Compositions and methods for the treatment of skin conditions," (Australian Patent Application No. 2019419387) continues to strengthen Dermata's global intellectual property portfolio for its Spongilla technology combination for the treatment of acne as it follows the Company's issued patent in the U.S. The patent will be automatically issued in mid-January 2026, unless a third party files an opposition within the three months after acceptance has been published.
Dermata's acne kit represents a new approach to acne treatment by targeting the underlying acne-driving mechanisms with enhanced precision and effectiveness. Unlike traditional therapies, this invention offers the potential for improved patient outcomes, reduced side effects, and broader accessibility, addressing a major unmet need in dermatology.
"This acceptance from the Australian patent office comes at a great time for our company as we embark on our new mission to provide patients with OTC pharmaceutical products that are backed by science," commented Gerry Proehl, Dermata's Chairman, President, and CEO. "With patents now issued in the United States and accepted in Australia, we are well-positioned to expand our development and commercial strategy, advancing toward our mission of providing safe, effective, and innovative solutions for patients worldwide. We believe a once-weekly, topical treatment regimen, with good tolerability, and demonstrated efficacy, like the acne kit we are currently developing, will be a disruptor to the acne market and provide patients with a unique treatment for their stubborn acne," concluded Mr. Proehl.
The acceptance of this patent application marks an important step in the Company's ongoing efforts to build a robust international patent estate, protecting its core acne treatment innovations in key markets. Additional patent filings are pending in other jurisdictions, which, if granted, will further solidify the Company's global intellectual property leadership in dermatology.
About Acne Vulgaris
There are over 3.3 million patients diagnosed with acne in Australia and over 30 million in the U.S., with about
About Dermata Therapeutics
Dermata Therapeutics is a scientific leader in dermatology that recently announced a strategic pivot to begin focusing on the development and distribution of OTC pharmaceutical skin treatments. The Company is currently developing a once-weekly acne kit that utilizes an active ingredient from the OTC monograph in combination with the Company's Spongilla technology to create a unique treatment option for patients suffering with acne. The Company plans to launch this initial acne kit in the middle of 2026 with additional product candidates planned to follow. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks that may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: expectations with regard to the potential market acceptance of any of the Company's product candidates; Dermata's shift to prioritize OTC dermatology products; the anticipated benefits of the strategic shift; the anticipated benefits of Dermata's strategic shift, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned or future OTC product launches; whether pending patent applications will proceed to allowance without interruption, if at all, and whether pending or issued patents will provide adequate protection for the Company's product candidates, if approved. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire
FAQ
What did Dermata (NASDAQ:DRMA) announce about its Australian patent application?
When will Dermata launch its new acne treatment product?
How many people are diagnosed with acne in Australia?
What makes Dermata's acne treatment different from traditional therapies?
What is the current status of Dermata's patent portfolio for its acne treatment?
